AbbVie Inc (ABBV)vsRani Therapeutics Holdings Inc (RANI)
ABBV
AbbVie Inc
$211.32
-2.23%
HEALTHCARE · Cap: $360.63B
RANI
Rani Therapeutics Holdings Inc
$0.94
+5.87%
HEALTHCARE · Cap: $108.42M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 3745154% more annual revenue ($61.16B vs $1.63M). ABBV leads profitability with a 6.9% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
RANI
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-26.3%
Fair Value
$163.59
Current Price
$211.32
$47.73 premium
Margin of Safety
+62.9%
Fair Value
$3.37
Current Price
$0.94
$2.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Revenue surging 42.1% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : RANI
The strongest argument for RANI centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 42.1% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : RANI
The primary concerns for RANI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while RANI is a hypergrowth play — different risk/reward profiles.
RANI carries more volatility with a beta of 0.66 — expect wider price swings.
RANI is growing revenue faster at 42.1% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 31/100). RANI offers better value entry with a 62.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Rani Therapeutics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rani Therapeutics Holdings Inc. is a pioneering biotechnology firm that revolutionizes injectable therapeutic delivery through its proprietary RaniPill™ technology, enabling the oral administration of biologics. This innovative platform not only enhances patient adherence but also improves treatment outcomes, effectively addressing critical gaps in the healthcare landscape. With a diverse pipeline targeting various therapeutic areas, Rani Therapeutics is well-positioned to disrupt conventional drug delivery methods while leveraging the increasing demand for non-invasive treatment solutions. Furthermore, the company's strategic collaborations and strong emphasis on research and development highlight its potential for substantial growth and meaningful contributions to the pharmaceutical sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?